Antonio Giaimo, MD

This segment looks ahead to remaining challenges in FCS diagnosis and access, and to the broader implications of APOC3 inhibition for hypertriglyceridemia management.

This segment emphasizes the clinical and quality‑of‑life value of achieving deep triglyceride reductions, particularly below 500 mg/dL, in FCS.

This segment addresses practical considerations in choosing between newly approved APOC3 inhibitors for patients with FCS.

This segment explores the mechanisms of APOC3‑targeting agents and compares the triglyceride‑lowering profiles of olezarsen and plozasiran in FCS.

This segment frames the longstanding unmet clinical need in FCS and the limitations of traditional management strategies.

This video segment outlines the clinical features of familial chylomicronemia syndrome and introduces the emerging role of novel triglyceride-lowering therapies.